For most of us, health has long been reduced to a single number on a scale. We wake up in the morning, step on, and brace ourselves, hoping for good news or dreading a reality check. But that number does…
When we talk about obesity, the conversation often turns to prescriptions—new drugs, new promises, new hope. But as SNAP benefits face new cuts and millions brace for another wave of food insecurity, we’re reminded of a truth the healthcare system…
GLP-1 receptor agonists (GLP-1 RAs) have changed the conversation around Type 2 diabetes and weight management. These injectable medications not only lower blood sugar, but they also reduce appetite, support weight loss, and have a positive impact on heart health.…
The global health and wellness conversation is changing fast. With the rise of GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro, weight management is being redefined through the lens of pharmacology. Once reserved for diabetes management, these medications have now become central…
A recent study from Virginia Tech analyzed how GLP-1 medications such as Ozempic, Wegovy, and Mounjaro affect alcohol absorption and perceived intoxication. Researchers measured breath alcohol levels and self-reported intoxication in adults with obesity, comparing participants taking GLP-1 drugs with…
For decades, artificial sweeteners have lived under the shadow of controversy. They have been accused of confusing the body, harming the gut, and even encouraging overeating. Headlines and social media have fueled this narrative, often without the depth of evidence…
In a major step forward for people with type 2 diabetes, MedPage Today reports that the FDA has approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk adults — whether or not they’ve had such an event already. That means…
For months, the national conversation around GLP-1 drugs has focused on one question: can anyone afford to stay on them long enough to see results? It’s a valid concern. Medications like semaglutide and tirzepatide have transformed obesity care, but their…